Patents Assigned to Fertin Pharma A/S
-
Patent number: 12194149Abstract: A water-dissolvable nicotine tablet is disclosed, the nicotine tablet comprising at least a first compressed module and a second compressed module, wherein the first compressed module is an FDT-module and comprises nicotine, alkaline pH regulating agent, and disintegrant, and, wherein the second compressed module is a lozenge-module and comprises acidic pH regulating agent. Also, a method of manufacturing a nicotine tablet is disclosed.Type: GrantFiled: September 11, 2023Date of Patent: January 14, 2025Assignee: Fertin Pharma A/SInventors: Kent Albin Nielsen, Rikke Pranger-Rasmussen, Dorthe Schackinger Boesen, Heidi Ziegler Bruun, Bruno Provstgaard Nielsen
-
Publication number: 20250009663Abstract: A mouthwash and method for oral care benefits includes a swishable powder delivery system having a content of at least two types of sugar alcohol particles with different particle size distributions and one or more active ingredients, the powder delivery system being a dry and flowable population of particles suitable for resembling a liquid mouthwash by swishing the powder delivery system, thereby generating fluid in the oral cavity without adding water.Type: ApplicationFiled: September 24, 2024Publication date: January 9, 2025Applicant: Fertin Pharma A/SInventors: Helle Wittorff, Christine Nøhr Pedersen
-
Publication number: 20250009650Abstract: A dissolvable orally adhering tablet for sustained release is disclosed, the tablet comprising an active ingredient, wherein the tablet is a multilayer tablet comprising a first layer and a second layer, the first layer being a mucoadhesive layer comprising a natural gum mucoadhesive and the second layer comprising at least one sugar alcohol.Type: ApplicationFiled: July 8, 2024Publication date: January 9, 2025Applicant: Fertin Pharma A/SInventor: Helle Wittorff
-
Publication number: 20250009767Abstract: An adhesive oral disc for sustained release of cannabinoids is presented. The disc includes one or more cannabinoids and is composed of at least a mucosal contacting layer having a mucosal contacting surface operable to be fixed to the gingiva of a person in need of alleviation or treatment of a medical condition, where the mucosal contacting layer includes one or more mucoadhesive polymers allowing the adhesive oral disc to adhere to the gingiva for an extended period of time. Further, the disc includes a non-mucoadhesive module fused to the mucosal contacting layer, where the non-mucoadhesive module includes a solid tablet composition allowing the non-mucoadhesive module to dissolve within an extended period of time upon adhesion of the adhesive oral disc to the gingiva. The invention is particularly useful for alleviation or treatment of ulcers.Type: ApplicationFiled: July 8, 2024Publication date: January 9, 2025Applicant: Fertin Pharma A/SInventors: Helle Wittorff, Sanne Skov Jensen, Gitte Nykjær Nikolajsen, Gordon Findlay Dawson
-
Publication number: 20240415853Abstract: An orally dissolvable or chewable tableted powder formulation is presented. The formulation includes one or more carrier systems including one or more liquid or solid self-emulsifying systems loaded with cannabinoids in an amount of at least 10% by weight of the tableted powder formulation. The one or more self-emulsifying systems includes: at least one or more surfactants, one or more lipids and one or more isolated or synthetic cannabinoids when the self-emulsifying system is a liquid self-emulsifying system, and at least one or more surfactants, one or more waxes and one or more isolated or synthetic cannabinoids when the self-emulsifying system is a solid self-emulsifying system. The formulation further includes one or more water-soluble agents in an amount of 20-80% by weight of the tableted powder formulation and one or more flavors.Type: ApplicationFiled: March 21, 2024Publication date: December 19, 2024Applicant: Fertin Pharma A/SInventors: Sanne Skov Jensen, Gitte Nykjær Nikolajsen, Simon Laursen, Dorthe Schackinger Boesen
-
Publication number: 20240415775Abstract: An oral chewable tablet contains dextrose in an amount from 50 to 95% by weight of the tablet; and one or more active ingredients in an amount from 0.1 to 50% by weight of the tablet. The oral chewable tablet includes at least two compressed layers containing the dextrose and the one or more active ingredients, the first of the compressed layers being cohered to and adjacent to the second layer.Type: ApplicationFiled: October 12, 2022Publication date: December 19, 2024Applicant: Fertin Pharma A/SInventor: Helle Wittorff
-
Patent number: 12156943Abstract: The invention relates to a tablet dosage form for buccal absorption of active ingredients comprising a population of particles and an active ingredient to be released in the oral cavity for absorption through the oral mucosa, the population of particles comprising directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles providing the tablet with a plurality of discrete non-DC areas.Type: GrantFiled: May 15, 2019Date of Patent: December 3, 2024Assignee: Fertin Pharma A/SInventor: Helle Wittorff
-
Patent number: 12128138Abstract: A mouthwash and method for oral care benefits includes a swishable powder delivery system having a content of at least two types of sugar alcohol particles with different particle size distributions and one or more active ingredients, the powder delivery system being a dry and flowable population of particles suitable for resembling a liquid mouthwash by swishing the powder delivery system, thereby generating fluid in the oral cavity without adding water.Type: GrantFiled: April 30, 2021Date of Patent: October 29, 2024Assignee: Fertin Pharma A/SInventors: Helle Wittorff, Christine Nøhr Pedersen
-
Publication number: 20240350404Abstract: An orally dissolvable or chewable tableted powder formulation, includes one or more mesoporous silica carriers loaded with a liquid cannabinoid suspension or solution; one or more water-soluble agents in an amount of 20-80% by weight of the tableted powder formulation; and one or more flavors, wherein the liquid cannabinoid suspension or solution includes one or more cannabinoids and one or more non-volatile solvents in a weight ratio of cannabinoid to solvent of 10:1 to 1:10.Type: ApplicationFiled: March 21, 2024Publication date: October 24, 2024Applicant: Fertin Pharma A/SInventors: Sanne Skov Jensen, Gitte Nykjær Nikolajsen, Simon Laursen, Dorthe Schackinger Boesen
-
Patent number: 12115155Abstract: The invention relates to an oral nicotine formulation for use in the alleviation of nicotine craving, the formulation comprising a content of nicotine and a content of a pH regulating agent, wherein the formulation provides a peak saliva concentration of nicotine of more than 0.3 mg/mL and a peak saliva pH of more than 7.5 during the first 120 seconds upon oral administration.Type: GrantFiled: December 7, 2018Date of Patent: October 15, 2024Assignee: Fertin Pharma A/SInventors: Bruno Provstgaard Nielsen, Kent Albin Nielsen
-
Patent number: 12109312Abstract: An oral tablet for taste masking of active ingredients includes a population of particles and an active ingredient with off-note taste. The population of particles includes directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles providing the tablet with a plurality of discrete non-DC areas, and the non-DC areas resulting at least partly in induced taste masking of the active ingredient upon mastication of the tablet.Type: GrantFiled: June 8, 2021Date of Patent: October 8, 2024Assignee: Fertin Pharma A/SInventor: Helle Wittorff
-
Patent number: 12102714Abstract: A disintegrating oral tablet suitable for active pharmaceutical ingredients includes a population of particles and at least one flavor ingredient. The population of particles includes directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles providing the tablet with a plurality of discrete non-DC areas, and the non-DC areas resulting in a burst of the at least one flavor ingredient upon mastication of the tablet.Type: GrantFiled: June 9, 2021Date of Patent: October 1, 2024Assignee: Fertin Pharma A/SInventor: Helle Wittorff
-
Publication number: 20240316077Abstract: An orally dissolvable or chewable tableted powder formulation is presented. The formulation includes one or more carrier systems including one or more liquid or solid self-emulsifying systems loaded with cannabinoids in an amount of at least 10% by weight of the tableted powder formulation. The one or more self-emulsifying systems includes: at least one or more surfactants, one or more lipids and one or more isolated or synthetic cannabinoids when self-emulsifying system is a liquid self-emulsifying system, and at least one or more surfactants, one or more waxes and one or more isolated or synthetic cannabinoids when self-emulsifying system is a solid self-emulsifying system. The formulation further includes one or more water-soluble agents in an amount of 20-80% by weight of the tableted powder formulation and one or more flavors. The one or more surfactants includes one or more surfactants having a chemical structure that includes a polyethylene glycol moiety.Type: ApplicationFiled: March 21, 2024Publication date: September 26, 2024Applicant: Fertin Pharma A/SInventors: Sanne Skov Jensen, Gitte Nykjær Nikolajsen, Simon Laursen, Dorthe Schackinger Boesen
-
Publication number: 20240285610Abstract: The invention relates to an orally disintegrating nicotine tablet for nicotine craving relief comprising a pressed powder formulation, the tablet being designed to disintegrate within a period of less than 60 seconds upon oral administration, the powder formulation comprising an amount of nicotine and a pH regulating agent.Type: ApplicationFiled: April 29, 2024Publication date: August 29, 2024Applicant: Fertin Pharma A/SInventors: Bruno Provstgaard Nielsen, Kent Albin Nielsen
-
Patent number: 12005058Abstract: The invention relates to an orally disintegrating nicotine tablet for nicotine craving relief comprising a pressed powder formulation, the tablet being designed to disintegrate within a period of less than 60 seconds upon oral administration, the powder formulation comprising an amount of nicotine and a pH regulating agent.Type: GrantFiled: July 7, 2023Date of Patent: June 11, 2024Assignee: FERTIN PHARMA A/SInventors: Bruno Provstgaard Nielsen, Kent Albin Nielsen
-
Patent number: 11911375Abstract: A solid oral nicotine formulation is disclosed, the formulation comprises a nicotine-ion exchange resin combination, and a salt comprising inorganic divalent cations, wherein the salt has a water-solubility of at least 5 grams per 100 mL of water measured at 25 degrees Celsius, atmospheric pressure and pH 7.0.Type: GrantFiled: November 16, 2020Date of Patent: February 27, 2024Assignee: FERTIN PHARMA A/SInventors: Kent Albin Nielsen, Jessie Poulsen
-
Publication number: 20240000706Abstract: A water-dissolvable compressed oral nicotine lozenge is disclosed, the oral nicotine lozenge comprising a first module and a second module, the first and the second modules being fused by compression, the first module being a lozenge module comprising at least one sugar alcohol and the second module being an FDT-module comprising at least one sugar alcohol and nicotine. Also, a method of manufacturing a water-dissolvable compressed oral nicotine lozenge is disclosed.Type: ApplicationFiled: August 3, 2023Publication date: January 4, 2024Applicant: Fertin Pharma A/SInventors: Dorthe Schackinger Boesen, Heidi Ziegler Bruun, Bruno Provstgaard Nielsen, Kent Albin Nielsen, Rikke Pranger-Rasmussen
-
Publication number: 20240000713Abstract: A water-dissolvable nicotine tablet is disclosed, the nicotine tablet comprising at least a first compressed module and a second compressed module, wherein the first compressed module is an FDT-module and comprises nicotine, alkaline pH regulating agent, and disintegrant, and, wherein the second compressed module is a lozenge-module and comprises acidic pH regulating agent. Also, a method of manufacturing a nicotine tablet is disclosed.Type: ApplicationFiled: September 11, 2023Publication date: January 4, 2024Applicant: Fertin Pharma A/SInventors: Kent Albin Nielsen, Rikke Pranger-Rasmussen, Dorthe Schackinger Boesen, Heidi Ziegler Bruun, Bruno Provstgaard Nielsen
-
Publication number: 20230346768Abstract: The invention relates to an orally disintegrating nicotine tablet for nicotine craving relief comprising a pressed powder formulation, the tablet being designed to disintegrate within a period of less than 60 seconds upon oral administration, the powder formulation comprising an amount of nicotine and a pH regulating agent.Type: ApplicationFiled: July 7, 2023Publication date: November 2, 2023Applicant: Fertin Pharma A/SInventors: Bruno Provstgaard Nielsen, Kent Albin Nielsen
-
Patent number: 11786473Abstract: A water-dissolvable nicotine tablet is disclosed, the nicotine tablet comprising at least a first compressed module and a second compressed module, wherein the first compressed module is an FDT-module and comprises nicotine, alkaline pH regulating agent, and disintegrant, and, wherein the second compressed module is a lozenge-module and comprises acidic pH regulating agent. Also, a method of manufacturing a nicotine tablet is disclosed.Type: GrantFiled: December 14, 2021Date of Patent: October 17, 2023Assignee: Fertin Pharma A/SInventors: Kent Albin Nielsen, Rikke Pranger-Rasmussen, Dorthe Schackinger Boesen, Heidi Ziegler Bruun, Bruno Provstgaard Nielsen